Catalog No.
Product Name
Application
Product Information
Citations
-
Telomerase Inhibitor
Braco-19 is a potent telomerase inhibitor that disrupts the capping and catalytic function of telomerase, leading to accelerated cellular senescence or selective cell death. As a G-quadruplex (GQ) binding ligand, Braco-19 effectively stabilizes G-quadruplex formation at the 3' telomeric DNA overhang, enhancing its biological activity. Additionally, Braco-19 demonstrates efficacy as an inhibitor of HAdV virus replication, making it a valuable tool for research in aging, cancer therapeutics, and virology studies. -
Viral DNA Polymerase Inhibitor
Foscarnet sodium, a viral DNA polymerase inhibitor, effectively suppresses viral replication through the reversible inhibition of polymerase activity. This compound is primarily utilized as an antiviral agent against herpesviruses, particularly in the treatment of cytomegalovirus retinitis. Its mechanism of action makes it a valuable tool for studying viral replication and evaluating therapeutic strategies against herpesvirus infections. -
Topoisomerase Inhibitor
Aclacinomycin A hydrochloride is a potent anthracycline antitumor antibiotic that primarily targets topoisomerase I and II. This compound inhibits nucleic acid synthesis, particularly RNA, and may also affect the 26S protease complex along with ubiquitin-ATP-dependent proteolysis. Due to its mechanisms of action, Aclacinomycin A hydrochloride serves valuable applications in cancer research and the study of cellular processes involving nucleic acids and proteolytic pathways. -
ATR PROTAC Degrader
PROTAC ATR degrader-2 is a selective degrader targeting the ATR protein. It effectively induces degradation of ATR in acute myeloid leukemia (AML) cell lines MV-4-11 and MOLM-13, demonstrating DC50 values of 22.9 nM and 34.5 nM, respectively. This compound has an IC50 of 29.6 nM against ATR, while exhibiting minimal activity against ATM and PI3K. PROTAC ATR degrader-2 promotes apoptosis, causes DNA damage, and upregulates p53 expression, thereby inhibiting cancer cell proliferation. This reagent is suitable for research applications focused on understanding mechanisms in acute myeloid leukemia. -
PARP10/PARP15 Inhibitor
PARP10/15-IN-3 is a dual inhibitor targeting PARP10 and PARP15, exhibiting IC50 values of 0.14 µM and 0.40 µM, respectively. This compound effectively penetrates cellular membranes and has demonstrated the ability to rescue cells from apoptosis. PARP10/15-IN-3 serves as a valuable tool for investigating the roles of PARP10 and PARP15 in cellular processes and offers potential applications in studies related to cancer therapy and cell survival mechanisms. -
eIF4A Inhibitor
rel-Zotatifin is a racemic isomer of Zotatifin, functioning as an inhibitor of the eukaryotic translation initiation factor 4A (eIF4A). This compound exhibits biological activity by promoting eIF4A binding to specific mRNA sequences in the 5’-UTRs, thereby disrupting the assembly of the eIF4F initiation complex. Its key research applications include the study of translation regulation and potential therapeutic interventions in conditions driven by aberrant protein synthesis. -
SIRT6 PROTAC Degrader
SZU-B6 is a SIRT6-protein-targeting chimeric degrader that achieves a DC50 of 45 nM and 154 nM in SK-HEP-1 and Huh-7 cell lines, respectively. It effectively inhibits the proliferation of SK-HEP-1 cells with an IC50 of 1.51 μM and suppresses colony formation in both SK-HEP-1 and Huh-7 cells. Additionally, SZU-B6 induces apoptosis and causes a cell cycle arrest in the G2/M phase in SK-HEP-1 cells, demonstrating notable antitumor efficacy in mouse models. This compound serves as a valuable tool for studying the functional roles of SIRT6 in cancer research. -
HDAC Class I Inhibitor
HDAC-IN-27 dihydrochloride is a potent inhibitor of class I histone deacetylases (HDAC1-3) with IC50 values ranging from 0.43 to 3.01 nM. This compound displays significant antitumor activity both in vitro and in vivo, particularly against acute myeloid leukemia (AML) cell lines, through mechanisms that include apoptosis induction and increased histone acetylation (AcHH3 and AcHH4). HDAC-IN-27 dihydrochloride is an important tool for investigating the roles of HDACs in cancer biology, specifically within the context of AML research. -
SIRT1 Inhibitor
JGB1741 is a potent and selective inhibitor of SIRT1, exhibiting an IC50 of approximately 15 μM. It displays weak inhibitory effects on SIRT2 and SIRT3, with IC50 values greater than 100 μM. JGB1741 enhances the levels of acetylated p53, promoting p53-mediated apoptosis through modulation of the Bax/Bcl2 ratio, cytochrome c release, and PARP cleavage. This compound is valuable for research applications focusing on breast cancer. -
DNA Topoisomerase I Inhibitor
Isodiospyrin is a natural dimeric naphthoquinone that functions as an inhibitor of human DNA topoisomerase I. By blocking DNA relaxation and the kinase activities of this enzyme, Isodiospyrin exhibits significant anticancer, antibacterial, and antifungal properties. This compound is valuable for research applications focused on cancer therapy and microbial resistance. -
PARP-1 Inhibitor
CEP-6800 is a potent inhibitor of PARP-1, known for its ability to enhance the efficacy of chemotherapeutic agents. It effectively reduces poly(ADP-ribose) accumulation induced by irinotecan and temozolomide in LoVo and HT29 xenograft models. Additionally, CEP-6800 demonstrates potential in suppressing tumor growth in Calu-6. This compound is valuable for research in cancer biology and therapy development. -
PARP
PARP-1/2-IN-1 is a highly effective inhibitor of the poly(ADP-ribose) polymerases PARP-1 and PARP-2, exhibiting IC50 values of 0.51 nM and 23.11 nM, respectively. This compound plays a critical role in cancer research by targeting DNA repair mechanisms, enhancing the efficacy of chemotherapeutic agents, and potentially improving cancer treatment outcomes. It is a valuable tool for studying PARP-related cellular processes and investigating therapeutic strategies in oncology. -
PARP-1/-2 inhibitor
CEP-9722 is a selective, orally active inhibitor of PARP-1 and PARP-2, exhibiting IC50 values of 20 nM and 6 nM, respectively. This compound demonstrates significant anticancer activity, making it a valuable tool for research in cancer therapy and DNA repair mechanisms. Its ability to inhibit these critical enzymes positions CEP-9722 as an important reagent for studying cellular responses to DNA damage and tumor susceptibility to therapeutic agents. -
PARP7 Inhibitor
PARP7-IN-21 is a potent inhibitor of PARP7, demonstrating an IC50 of less than 10 nM. This compound effectively interferes with the activity of PARP7, which is involved in the regulation of cellular processes such as DNA repair and signaling pathways related to stress response. PARP7-IN-21 is valuable for research applications focused on cancer biology, neurodegenerative diseases, and other conditions associated with PARP7 dysregulation. -
CDK9/PARP Inhibitor
CDK9/PARP-IN-1 is a potent inhibitor of CDK9 and PARP1, demonstrating IC50 values of 118 nM and 107 nM, respectively. This dual inhibition results in significant antiproliferative effects across various cancer cell lines, making it a valuable tool for cancer research. CDK9/PARP-IN-1 is particularly relevant for studies investigating the therapeutic potential of targeting these pathways in oncology. -
PARP1/CDK12 Inhibitor
Antitumor agent-104 is a potent inhibitor of PARP1 and CDK12, targeting critical pathways in DNA damage repair in tumors. By inhibiting PARP1 enzymatic activity, it effectively reduces PAR protein levels, thus impairing the cellular mechanisms that protect tumor cells. This compound serves as a valuable tool in cancer research, especially in studies focused on understanding tumor biology and exploring novel therapeutic strategies. -
PARP1 Inhibitor
PARP1-IN-53 is a potent PARP1 inhibitor with an IC50 of 0.1 nM, demonstrating high selectivity over PARP2, which has an IC50 of 23 nM. This quinazolinone derivative effectively interferes with the poly(ADP-ribose) polymerase 1 enzyme, making it a valuable compound for cancer research. Its specific action on PARP1 enables detailed studies into the mechanisms of DNA repair and cell survival in oncology. -
PARP PROTAC Degrader
PROTAC PARP1 degrader-2 is a targeted protein degradation compound designed to specifically degrade PARP1. With a DC50 of less than 10 nM in MDA-MB-231 cells, it demonstrates potent efficacy in inducing degradation. Additionally, this compound inhibits cell viability in MDA-MB-436 cells with an IC50 of less than 100 nM, making it a valuable tool for research in cancer therapeutics and the mechanistic study of PARP1 function. -
PARP Inhibitor
INO-1001 mesylate is a selective inhibitor of poly (ADP-ribose) polymerase (PARP), a critical enzyme involved in DNA repair processes. It enhances the sensitivity of cancer cells to radiation therapy by disrupting DNA repair mechanisms, leading to increased necrotic cell death. This compound is of interest in cancer research, particularly in studies aimed at overcoming resistance to radiation and improving therapeutic outcomes in tumorigenesis. -
PARP-1/2 Inhibitor
CEP-8983 is a potent inhibitor of PARP-1 and PARP-2, with IC50 values of 20 nM and 6 nM, respectively. This compound effectively enhances the sensitivity of chemotherapy-resistant cell lines and subcutaneous xenograft models to the anticancer agents Temozolomide and Camptothecin. Its ability to disrupt DNA repair mechanisms makes CEP-8983 a valuable tool for cancer research, particularly in studies focusing on therapeutic resistance and combination therapies. -
PARP-1 Inhibitor
ST7710AA1 is a potent inhibitor of PARP-1, exhibiting an IC50 value of 0.07 µM. This compound demonstrates significant antiproliferative and anticancer activity, making it a valuable tool for research in oncology and cellular biology. Its ability to inhibit PARP-1 can be leveraged to explore mechanisms of cancer cell survival and the effects of DNA damage repair pathways. -
PARP-1 Inhibitor
8-Chloroquinazolin-4-ol is a potent inhibitor of the PARP-1 enzyme, exhibiting an IC50 value of 5.65 μM. This compound serves as a nicotinamide mimic and plays a significant role in research focused on DNA repair mechanisms and cancer therapies. Its ability to modulate PARP-1 activity makes it a valuable tool for exploring therapeutic strategies in various disease models. -
PARP-1 Inhibitor
Benzo[c][1,8]naphthyridin-6(5H)-one is a potent inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1) and aurora kinase A, exhibiting IC50 values of 0.311 μM and 5.5 μM, respectively. This compound demonstrates low micromolar affinity for human adenosine receptors AR A1 and hA2A, with Ki values of 4.6 and 4.8 μM. Due to its mechanistic action, Benzo[c][1,8]naphthyridin-6(5H)-one is valuable for research applications targeting DNA repair pathways and cancer therapies. -
PARP-1 Inhibitor
BSI-401 is an orally active inhibitor of PARP-1, a key enzyme involved in DNA repair processes. This compound demonstrates significant anti-cancer activity, particularly in pancreatic cancer, both as a monotherapy and in combination with Oxaliplatin. BSI-401 is valuable for research into therapeutic strategies targeting DNA damage response pathways in cancer treatment. -
PARP-2 Inhibitor
UPF-1035 is a selective inhibitor of PARP-2, exhibiting an IC50 value of 0.15 μM. This compound has been shown to increase CA1 pyramidal cell loss in the hippocampus, indicating its role in neuroprotection. UPF-1035 can be utilized in research focused on neurodegenerative diseases and the mechanisms of neuronal cell survival. -
PARP1 Inhibitor
PARP1-IN-19 is a potent inhibitor of poly (ADP-ribose) polymerase 1 (PARP1), a key enzyme involved in DNA repair mechanisms. This compound exhibits significant antitumor activity, making it a valuable tool in cancer research and therapeutic development. It is primarily utilized in studies focusing on the modulation of DNA damage response pathways and the exploration of combination therapies in oncology. -
PARP Inhibitor
NU1064 dihydrochloride is a selective inhibitor of poly(ADP-ribose) polymerase (PARP), an enzyme involved in DNA repair mechanisms. This compound enhances the cytotoxic effects of DNA-methylating agents, such as MTIC, in a concentration-dependent manner. It is valuable for research in cancer biology, particularly in studies focusing on enhancing the efficacy of chemotherapeutic agents and understanding mechanisms of DNA repair inhibition. -
PARP Inhibitor
KU-0058684 is a selective PARP inhibitor, exhibiting an IC50 of 3.2 nM for PARP-1. This reagent effectively impairs DNA double strand break repair, making it a valuable tool for investigating DNA damage response mechanisms. Its application extends to studying the therapeutic potential of PARP inhibition in various cancer models. -
PARP Inhibitor
WD2000-012547 is a selective inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1), demonstrating a pKi value of 8.221. This compound effectively interferes with PARP-1 activity, which plays a crucial role in DNA repair and cellular response to DNA damage. WD2000-012547 is instrumental in research applications involving cancer therapeutics, where modulation of DNA repair pathways is of significant interest. -
PARP2 Inhibitor
OUL245 is a selective inhibitor of PARP2, exhibiting an IC50 of 44 nM. It also demonstrates inhibitory activity against other PARP family members and TNKS enzymes, with IC50 values ranging from 2.9 to 8.8 μM. This compound is valuable for research into DNA repair mechanisms and the therapeutic potential of targeting PARP enzymes in various cancer models. -
PARP-1 Inhibitor
5-AIQ hydrochloride is a selective inhibitor of PARP-1, an important enzyme involved in DNA repair. This compound exhibits protective effects against ischemia-reperfusion injury in liver tissue, making it a valuable tool for studying conditions related to hepatic ischemia-reperfusion. Its applications extend to research focused on oxidative stress and cell survival mechanisms, providing insights into potential therapeutic strategies for liver protection. -
PARP1 Inhibitor
PARP1-IN-22 is a highly potent inhibitor of poly (ADP-ribose) polymerase 1 (PARP1) with an IC50 of less than 10 nM. This compound is utilized in research focused on DNA damage repair pathways and cellular responses to oxidative stress. Its ability to inhibit PARP1 makes it valuable for studies in cancer therapy and neurodegenerative diseases, where modulation of DNA repair mechanisms is crucial. -
PARP Inhibitor
A-620223 succinate is a potent inhibitor of poly(ADP-ribose) polymerase (PARP), targeting the PARP-1 enzyme with a Ki value of 8 nM and an EC50 value of 3 nM in cellular assays. Its excellent selectivity and bioavailability make it an invaluable tool for cancer research, enabling investigations into DNA repair mechanisms and potential therapeutic strategies. This compound is particularly useful in studies focused on the efficacy of PARP inhibition in various cancer models. -
PARP1 Degrader
SK-575-NEG is a PARP1 degrader designed as a methylated counterpart of SK-575, synthesized through the methylation of the amino group in piperidine-2,6-dione. It demonstrates a strong binding affinity to PARP1, with an IC50 of 2.64 nM. However, SK-575-NEG does not induce PARP1 degradation in MDA-MB-436 and Capan-1 cell lines at concentrations up to 1 μM. This compound is valuable for research focusing on the mechanistic understanding of PARP1 inhibition and degradation pathways. -
PARP14 Inhibitor
PARP14 Inhibitor 2 is a highly selective inhibitor targeting PARP14 with an IC50 value of less than 30 nM. This compound effectively inhibits the mono-ADP-ribosyltransferase activity of PARP14, thereby modulating signaling pathways associated with IFN-γ and IL-4. By reversing protumor macrophage polarization and inhibiting pro-inflammatory responses, PARP14 Inhibitor 2 holds promise for the investigation of diseases related to PARP14, including tumors, atopic dermatitis, and autoimmune disorders. -
PARP1 Inhibitor
PARP1-IN-36 is a selective inhibitor of PARP-1, characterized as a 4-carboxamido-isoindolinone derivative with a Kd value of less than 0.01 μM. This compound exhibits significant biological activity in the modulation of cellular processes associated with DNA repair, making it a valuable tool in research focused on cancer, cardiovascular diseases, nervous system injury, and inflammation. Its potent inhibition of PARP-1 serves to elucidate the role of this enzyme in various pathological contexts. -
PARP-1 Inhibitor
6(5H)-Phenanthridinone is a potent inhibitor of PARP-1, a key enzyme involved in DNA repair processes. This compound exhibits significant immunomodulatory effects and has been shown to inhibit cell proliferation. It is employed in cancer research to explore therapeutic strategies targeting DNA repair pathways and to enhance the efficacy of chemotherapeutic agents. -
PARP1/2 Inhibitor
PARP1/2-IN-3 is a potent inhibitor of PARP1 and PARP2, exhibiting IC50 values of 0.2235 nM and <0.001 nM, respectively. This compound effectively inhibits the proliferation of Capan-1 wildtype and AZD2281 or BMN673-resistant cells, with IC50 values ranging from 1.82 to 9.98 nM. Additionally, PARP1/2-IN-3 demonstrates significant antitumor efficacy in murine models, making it a valuable tool for cancer research and therapeutic development targeting PARP pathways. -
CDK-1/PARP-1 Inhibitor
UNPD139734 is a potent inhibitor of Cyclin-Dependent Kinase 1 (CDK-1) and Poly (ADP-ribose) polymerase 1 (PARP-1), forming stable complexes with both target proteins. This compound serves as a valuable lead for the structural optimization of dual-target anticancer agents, particularly in the context of breast cancer research. Its dual inhibition mechanism offers a promising avenue for investigating novel therapeutic strategies in oncology. -
PARP1/2/7 Inhibitor
PARP-1/2/7-IN-1 is a highly potent inhibitor of poly (ADP-ribose) polymerases PARP-1, PARP-2, and PARP-7, demonstrating an IC50 of less than 10 nM. This compound is valuable for research applications focused on cancer biology, DNA repair mechanisms, and cellular stress responses. Its multifunctional inhibition can aid in the exploration of therapeutic strategies targeting PARP-mediated pathways in various diseases. -
PARP1 Inhibitor
PARP1-IN-48 is a potent and selective inhibitor of poly(ADP-ribose) polymerase 1 (PARP1), exhibiting an IC50 of 3 nM against PARP1 and 170 nM against PARP2. This compound is valuable for research in oncology, virology, and metabolic disorders, facilitating investigations into the role of PARP1 in DNA repair and cellular stress responses. Its selective action makes it an essential tool for studying therapeutic pathways in cancer treatment and other disease models. -
PARP1 Inhibitor
PARP1-IN-30 is a potent, selective inhibitor of PARP1 that exhibits cytotoxic effects in tumor cells. It effectively targets cancer cells with deficiencies in the breast cancer 1 protein (BRCA1) or BRCA2, offering a valuable tool for elucidating the role of PARP1 in DNA repair and cancer biology. This compound is particularly relevant for research applications focused on targeted cancer therapies and synthetic lethality in oncology. -
PARP Inhibitor
ARTD10/PARP10-IN-2 is a potent and non-selective inhibitor of the poly(ADP-ribose) polymerases, specifically targeting ARTD10/PARP10 and ARTD1/PARP1. With IC50 values of 2.0 μM and 9.7 μM, respectively, this compound effectively modulates mono-ADP-ribosyltransferase and poly(ADP-ribose) polymerase activities. Its ability to inhibit these pathways makes ARTD10/PARP10-IN-2 valuable for research on DNA repair mechanisms and therapeutic approaches in cancer treatment. -
PARP1 Inhibitor
ZINC000081009201 is a potent inhibitor of poly(ADP-ribose) polymerase 1 (PARP1) with an IC50 value of 1.4767 μM. This compound demonstrates significant potential for the study of triple-negative breast cancer (TNBC) by targeting PARP1-mediated repair pathways. Its inhibition may aid in elucidating the mechanisms of resistance and sensitivity in cancer treatment, making it a valuable tool for cancer research applications. -
PARP7 Inhibitor
PARP7-IN-18 is a potent selective inhibitor of PARP7, exhibiting an IC50 value of 0.11 nM. This compound demonstrates significant anticancer activity, making it a valuable tool for research applications focused on cancer biology and the therapeutic potential of targeting PARP7. Its favorable pharmacokinetic properties further enhance its utility in in vivo studies and drug development. -
PARP Inhibitor
NU 1085 is a potent poly(ADP-ribose) polymerase (PARP) inhibitor with an impressive Ki of 6 nM. This compound exhibits significant cytotoxicity towards cancer cells, with an LC50 between 83-94 μM. Additionally, NU 1085 has the potential to enhance the anticancer effects of Temozolomide, making it a valuable tool for cancer research, particularly in the study of lung cancer and other malignancies. -
PARP1 Inhibitor
PARP1-IN-20, a selective PARP1 inhibitor, exhibits a potent inhibitory effect with an IC50 of 4.62 nM. This compound demonstrates minimal PARP-Trapping activity compared to other known inhibitors, including a significant threshold of >100 μM in the MDA-MB-436 cell line. PARP1-IN-20 is suitable for research applications focused on cancer therapy and DNA damage repair mechanisms. -
Conjugate Compound with PARP Inhibitor
ADP-ribose/PARP-IN-1 is a conjugated compound that combines disease-targeting moieties with PARP inhibitor functionality. This reagent selectively delivers PARP inhibitors to tumor cells, facilitating the inhibition of PARP enzymes that are critical for DNA damage repair. The presence of a cleavable linker ensures the release of the PARP inhibitor under specific conditions, while the chelator component enables the accumulation of radionuclides that exert cytotoxic effects. ADP-ribose/PARP-IN-1 is a valuable tool for research into prostate cancer and other malignancies characterized by PARP dependency. -
PARP Inhibitor
LT-626 is a potent poly(ADP-ribose) polymerase (PARP) inhibitor, with an IC50 of 1.60 nM. This inhibitor effectively reduces cellular poly(ADP-ribose) synthesis, demonstrating an EC50 of 17.9 nM, and displays enhanced cytotoxicity in colorectal cancer cells with MRE11 mutations. Additionally, LT-626 exhibits synergistic effects when combined with chemotherapeutic agents such as Cisplatin, Oxaliplatin, and SN-38, making it a valuable tool for colorectal cancer research applications. -
PARP7 Inhibitor
RBN010860 is a potent inhibitor of PARP7, exhibiting an IC50 value of less than 0.1 μM. This reagent serves as a valuable tool for investigating the role of PARP7 in cancer biology, enabling researchers to explore its potential as a therapeutic target in oncological studies.
